Table 2

Study characteristics of model development studies: analysis and model output

StudyOutcome(s) or endpoint(s)Time frame of predictionsModel typeStatistical methodsIncluded predictorsMissing data handlingNumber of groupsInternal validation methodDiscrimination results (c-index or AUC)Calibration resultsModel availability
Margel et al 201421 PCSM and ACM5 yearN/ANested Cox modelTwo models: 1=age, Johns Hopkins comorbidity group, year of cohort entry, socioeconomic status and housing status. 2=as above + Gleason grade and cancer volume.Complete case analysisN/ABootstrappingAdmin data only model ACM c-index 0.70 (95% CI 0.69 to 0.71) PCSM 0.76 (95% CI 0.74 to 0.78)
Extended model ACM 0.74 (95% CI 0.73 to 0.75)
PCSM: 0.85 (95% CI 0.83 to 0.87)
NRNo
Nguyen et al 200922 PCSM and ACM5 yearGroup-based stratificationFine & GreyPSA, PSAV, stage, GleasonNRfour groupsKM curves onlyNRNRYes - paper
Feuer et al 201223 PCSM, OCM and LE3–5 and 10 yearNomogramCox modelPreclinical model: stage, Gleason, age, race, marital status, (comorbidity if 66+)Complete case analysis‘Individualised’Time dependent AUC10 year AUCs: Pretreatment model: <66 years, PCSM 0.82, OCM 0.69, 66+yrs PCSM 0.87, OCM 0.61PlotsNo
Kutikov et al 201224 PCSM and NPCM10 yearNomogramFine & GreyAge, race, comorbidity, primary treatment (RT vs RP), receipt of ADT and modified CAPRA scoreImputed mean valuesNomogramNRNRNRYes - paper
Cowen et al 200625 Overall survival5, 10 and 15 year and median LENomogramCox modelAge, Charlson, performance status, angina, BMI, smoking, marital status, PSA, Gleason, treatmentImputation260 pointsWithin complete case sub-cohortc-index 0.73PlotsYes - paper
Kerkmeijer et al 201626 DSS and OS10 year DSSNomogramCox modelT-stage, grade(on 1–3 scale) PSA, ageSingle imputation16 points - five groupsBootstrappingc-index 0.78 (95% CI 0.74 to 0.82) DSS, 0.68 (95% CI 0.65 to 0.70) OSPlotsYes - paper
Gnanapragasam et al 201627 PCSMN/AGroup-based stratificationCox modelPSA, grade group, T-stage integersComplete case analysisfive groupsRandom validation cohortc-index 0.75 (95% CI 0.72 to 0.77) for PCSMPlotsYes - paper and online model
Tewari et al 200428 PCSM and ACM10 yearLook up tablesCox modelAge, grade (three groups), PSA, treatment, comorbidity, raceComplete case analysisn/aUnclear0.63 PCSM, 0.69 OSNRYes - paper
Howlader et al 201429 OS, PCa death, other cause death5 yearLook up tablesUnclearAge, stage (localised/regional/distant), comorbidityNRn/aNRNRNRYes - paper
  •  ACM, all cause mortality; AUC, area under the curve; BMI, body mass index; CAPRA, Cancer of the Prostate Risk Assessment; DSS, disease specific survival; KM, Kaplan-Meier; LE, life expectancy; N/A, not available; NPCM, non prostate cancer mortality; NR, not recorded; OCM, other cause mortality; OS, overall survival; PCa, prostate cancer; PCSM, prostate cancer specific mortality; PSA, prostate-specific antigen; PSAV, prostate-specific antigen velocity.